The study compound may potentially be used for the treatment of diseases caused by abnormalities of blood vessels. Vascular malformation is a rare condition that affects the vascular system, which include veins, arteries and lymph vessels. These malformations are a result of the abnormal growth and development of a single type of vessel or a combination of vessels. Instead of normal, smooth networks of vessels, the vessels enlarge or develop an abnormal shape and structure that cause abnormal blood flow. Over the years, malformations can grow larger and become problematic depending on the type of vessel.

• You are a healthy male.
• You are at least 18 and no more than 65 years old.
• Your Body Mass Index (BMI) is higher than or equal to 18.0 and lower than or equal to 30.0 kg/m². The BMI shows the relationship between body weight in kilograms and height in meters.
• Both non-smokers and light or occasional smokers (max. 5 cigarettes, 1 cigar or 1 pipe per day) are allowed to participate in this clinical trial. During your stay in our research facility you are not allowed to smoke.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first compound administration in this clinical trial (counting from the follow-up visit of the previous trial).
• You can only participate in this trial if you have not participated in another trial with a radioactive (14C) labeled compound in the past 12 months. If a compound with a negligible radioactivity amount was administered in a previous study, you might be allowed to participate. Please contact us for more information.
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.
• You can only participate if you meet one of the following conditions:
  • You are using a condom in combination with an additional contraception method used by your female partner;
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.

The trial consists of 1 period during which you will stay in the research facility in Groningen for 16 days (15 nights). Depending on the radioactivity levels in your body at the end of the stay, you may have to return to the research facility for a maximum of four 24-hour visits, until radioactivity levels are low enough. The follow-up visit will take place between 7 to 9 days after your last departure from the research facility.

Note: You must be available for all dates to be able to participate in this clinical trial